Our Publications
Local chemotherapy in treatment of brain tumors. Part 2. Efficiency of treatment of patients with neuroepithelial brain tumors secondary to intraoperative local chemotherapy
According to the results of open, controlled, retro prospective, comparative, randomized clinical trial found an increase in the efficacy of the combined treatment of malignant brain tumors in the application of intraoperative local chemotherapy drug (LHT) temodex. In particular, the median survival of patients with Grade III–IV tumors in the supratentorial localization background intraoperative LHT increased when radical resection of the tumor with 11.15 months to 78.6 19.65 months. When subtotal resection of this figure increased to 9.025 months to 17.23 months, with convexital dissemination process – from 10.0 months to 19.65 months, and on the paraventricular location[...]
Local chemotherapy in treatment of brain tumors. Part 1. Characteristics of neurosurgical intervention and the course of the postoperative period in patients with brain tumors secondary to local chemotherapy
The assessment of the clinical progression of the postoperative period in patients with neuroepithelial brain tumors when using intraoperative local chemotherapy (iLCT) with Temodex, which is an anticancer medicinal product of the active substance of temozolomide immobilized on highly substituted dextran phosphate. Clinical manifestations and features of the early postoperative period were analyzed depending on the radicality of tumor resection, its localization and extension. Complications and causes of mortality were studied in patients undergoing standard surgery and iCLT. It was shown that the frequency and nature of complications when using Temodex did not differ from those in the control[...]
Local delivery of temozolomide via a biologically inert carrier (Temodex)
Glioma is the most common brain malignancy. Standard first-line therapy for glioma includes surgery, radiotherapy and systemic administration of temozolomide. However, temozolomide does not reach the brain in sufficient doses when administered orally and has poor efficiency in more than half of the patients. Strategies to improve the treatment of glial malignancies are therefore needed. We have recently developed a system (Temodex) for local administration of temozolomide by encapsulating the drug in a biologically inert matrix. Here, we assessed the effect of Temodex in combination with standard therapy in a small-scale clinical study. Since the efficacy of temozolomide[...]
Cancer neuroscience and glioma (2025)
In recent years, it has been increasingly recognized that tumor growth relies not only on support from the surrounding microenvironment but also on the tumors capacity to adapt to - and actively manipulate - its niche. While targeting angiogenesis and modulating the local immune environment have been explored as therapeutic approaches, these strategies have yet to yield effective treatments for brain tumors and remain under refinement. More recently, the nervous system itself has been explored as a critical environmental support for cancer, with extensive neuro-tumoral interactions observed both intracranially and in extracranial sites containing neural components. In the[...]
Temodex prolongs survival in glioma patients 2019
Temodex prolongs survival in glioma patients 2019 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter Information on Double Bond Pharmaceutical International AB DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug[...]
Our expert view on Drug Delivery 2017
Our expert view on Drug Delivery 2017 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter Information on Double Bond Pharmaceutical International AB DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug[...]